| Trial ID: | L1876 |
| Source ID: | NCT01392560
|
| Associated Drug: |
Bi 10773
|
| Title: |
Safety and Efficacy of Empagliflozin (BI 10773) in Type 1 Diabetes Mellitus Patients With or Without Renal Hyperfiltration
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT01392560/results
|
| Conditions: |
Diabetes Mellitus, Type 1
|
| Interventions: |
DRUG: BI 10773
|
| Outcome Measures: |
Primary: Change in Glomerular Filtration Rate (GFR) After 8 Weeks of Treatment With Empagliflozin Under Controlled Conditions of Euglycaemia and Hyperglycaemia, The primary endpoint is change in glomerular filtration rate (GFR) after 8 weeks of treatment with empagliflozin under controlled conditions of euglycaemia and hyperglycaemia, Baseline and 8 weeks |
|
| Sponsor/Collaborators: |
Sponsor: Boehringer Ingelheim
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE2
|
| Enrollment: |
52
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2011-06
|
| Completion Date: |
2012-08
|
| Results First Posted: |
2014-06-17
|
| Last Update Posted: |
2014-06-17
|
| Locations: |
1245.46.10001 Boehringer Ingelheim Investigational Site, Toronto, Ontario, Canada
|
| URL: |
https://clinicaltrials.gov/show/NCT01392560
|
